Your browser doesn't support javascript.
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Chen, Rita E; Winkler, Emma S; Case, James Brett; Aziati, Ishmael D; Bricker, Traci L; Joshi, Astha; Darling, Tamarand L; Ying, Baoling; Errico, John M; Shrihari, Swathi; VanBlargan, Laura A; Xie, Xuping; Gilchuk, Pavlo; Zost, Seth J; Droit, Lindsay; Liu, Zhuoming; Stumpf, Spencer; Wang, David; Handley, Scott A; Stine, W Blaine; Shi, Pei-Yong; Davis-Gardner, Meredith E; Suthar, Mehul S; Knight, Miguel Garcia; Andino, Raul; Chiu, Charles Y; Ellebedy, Ali H; Fremont, Daved H; Whelan, Sean P J; Crowe, James E; Purcell, Lisa; Corti, Davide; Boon, Adrianus C M; Diamond, Michael S.
  • Chen RE; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Winkler ES; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
  • Case JB; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Aziati ID; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
  • Bricker TL; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Joshi A; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Darling TL; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Ying B; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Errico JM; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Shrihari S; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • VanBlargan LA; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
  • Xie X; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Gilchuk P; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Zost SJ; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Droit L; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Liu Z; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Stumpf S; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Wang D; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Handley SA; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Stine WB; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Shi PY; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
  • Davis-Gardner ME; AbbVie Bioresearch Center, Worcester, MA, USA.
  • Suthar MS; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
  • Knight MG; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
  • Andino R; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.
  • Chiu CY; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Ellebedy AH; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Fremont DH; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
  • Whelan SPJ; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
  • Crowe JE; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Purcell L; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Corti D; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
  • Boon ACM; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St Louis, MO, USA.
  • Diamond MS; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St Louis, MO, USA.
Nature ; 596(7870): 103-108, 2021 08.
Article in English | MEDLINE | ID: covidwho-1275940
ABSTRACT
Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures. Although cell culture experiments have demonstrated a loss of potency of several anti-spike neutralizing antibodies against variant strains of SARS-CoV-21-3, the in vivo importance of these results remains uncertain. Here we report the in vitro and in vivo activity of a panel of monoclonal antibodies (mAbs), which correspond to many in advanced clinical development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron and Lilly, against SARS-CoV-2 variant viruses. Although some individual mAbs showed reduced or abrogated neutralizing activity in cell culture against B.1.351, B.1.1.28, B.1.617.1 and B.1.526 viruses with mutations at residue E484 of the spike protein, low prophylactic doses of mAb combinations protected against infection by many variants in K18-hACE2 transgenic mice, 129S2 immunocompetent mice and hamsters, without the emergence of resistance. Exceptions were LY-CoV555 monotherapy and LY-CoV555 and LY-CoV016 combination therapy, both of which lost all protective activity, and the combination of AbbVie 2B04 and 47D11, which showed a partial loss of activity. When administered after infection, higher doses of several mAb cocktails protected in vivo against viruses with a B.1.351 spike gene. Therefore, many-but not all-of the antibody products with Emergency Use Authorization should retain substantial efficacy against the prevailing variant strains of SARS-CoV-2.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neutralization Tests / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03720-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Neutralization Tests / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03720-y